Hurler's Syndrome

719 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Synonym: mucopolysaccharidosis type IH, mucopolysaccharidosis I, MPS I

The mucopolysaccharidoses are a group of inherited disorders caused by a lack of specific lysosomal enzymes involved in the degradation of glycosaminoglycans (GAGs). Deficiency of alpha-L-iduronidase can result in a wide range of phenotypes including Hurler's (severe), Scheie's (mild) and Hurler-Scheie (intermediate) syndromes.[1] The genetic defect involves a mutation in the gene IDUA that encodes alpha-L-iduronidase on chromosome 4.

  • One study, using a unique longitudinal data set, initiated and maintained over a period of more than 20 years by the Society for Mucopolysaccharide Diseases (UK), found a birth prevalence in England and Wales of 1.07/100,000.[2]
  • The mode of inheritance is autosomal recessive.

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »

Affected children appear normal at birth but usually develop the characteristic appearance within the first year of life. The median age of onset of symptoms is 6 months.[3] 

  • General learning disability: maximum functional development is reached when the child is aged between 2 and 4 years.
  • Short stature.
  • Coarse facies and enlarged tongue.
  • Corneal clouding.
  • Hearing impairment.
  • Umbilical and inguinal hernias.
  • Joint stiffness and skeletal deformities.
  • Cardiomyopathy and coronary heart disease.
  • Hepatosplenomegaly.
  • Dysostosis multiplex: enlarged skull, enlarged but shortened bones, malformed pelvis, and other skeletal defects.
  • Urine: raised levels of dermatan sulfate and heparan sulfate (metabolites related to GAG) are found in patients with mucopolysaccharidoses.
  • Lymphocytes examined in blood smears may show abnormal cytoplasmic inclusions.
  • Definitive diagnosis is established by alpha-L-iduronidase enzyme assay using artificial substrates in cultured fibroblasts or isolated leukocytes.
  • Carrier testing can be performed by differentiating normal enzyme activity from half-normal levels of enzyme activity.
  • Prenatal diagnosis: using cultured amniotic fluid cells or chorionic villus biopsies.
  • Molecular diagnosis: difficult because of genetic heterogeneity.
  • Assessment of complications will include an echocardiogram and MRI brain scan.
  • In severe cases, radiography of the skeleton (especially the spine) may detect a gibbus deformity of the lower spine.
  • A mild form of dysostosis multiplex may be seen on X-ray.
  • Ultrasound imaging of the ophthalmic nerve sheath and sclera is a useful technique for assessing the presence of morphological changes.[5]
  • Palliative treatment includes the provision of multidisciplinary treatment and support for affected children and their families.
  • Orthopaedic surgery for joint contractures and skeletal deformities.
  • Other surgical procedures may include myringotomy, hernia repair and adenoidectomy/tonsillectomy.[6]
  • Corneal transplants may be required.
  • Enzyme replacement therapy with laronidase can be used pre- and peri-haemopoietic stem cell transplant, which is now the gold standard treatment in those patients diagnosed under 2.5 years of age.[7][8][9] 
  • Gene therapy may present treatment possibilities in the future.[4] 
  • Orthopaedic complications lead to pain and immobility.
  • Upper airways obstruction; progressive airway, craniofacial and skeletal abnormalities may make both ventilation and intubation difficult.[10] 
  • Increased susceptibility to infections of the respiratory tract.
  • There is a high morbidity and mortality, causing in many cases severe neurological and somatic damage in the first years of life.[11] 
  • The median survival for mucopolysaccharidosis I (MPS I) patients is 11.6 years.[2]
  • Common causes of death include upper airways obstruction, cardiac insufficiency and respiratory tract infections.

Further reading & references

  1. Mucopolysaccharidosis Type IH, MPS1-H; Online Mendelian Inheritance in Man (OMIM)
  2. Moore D, Connock MJ, Wraith E, et al; The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie Orphanet J Rare Dis. 2008 Sep 16;3:24.
  3. Beck M, Arn P, Giugliani R, et al; The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014 Oct;16(10):759-65. doi: 10.1038/gim.2014.25. Epub 2014 Mar 27.
  4. Wraith JE, Jones S; Mucopolysaccharidosis type I. Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:102-6.
  5. Schumacher RG, Brzezinska R, Schulze-Frenking G, et al; Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol. 2008 May;38(5):543-50. Epub 2008 Feb 26.
  6. Arn P, Wraith JE, Underhill L; Characterization of surgical procedures in patients with mucopolysaccharidosis J Pediatr. 2009 Jun;154(6):859-64.e3. Epub 2009 Feb 12.
  7. Watson HA, Holley RJ, Langford-Smith KJ, et al; Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in Mucopolysaccharidosis-I. J Biol Chem. 2014 Oct 30. pii: jbc.M114.599944.
  8. de Ru MH, Boelens JJ, Das AM, et al; Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011 Aug 10;6:55. doi: 10.1186/1750-1172-6-55.
  9. Jameson E, Jones S, Wraith JE; Enzyme replacement therapy with laronidase (Aldurazyme((R))) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2013 Nov 21;11:CD009354. doi: 10.1002/14651858.CD009354.pub3.
  10. Gurumurthy T, Shailaja S, Kishan S, et al; Management of an anticipated difficult airway in Hurler's syndrome. J Anaesthesiol Clin Pharmacol. 2014 Oct;30(4):558-561.
  11. Campos D, Monaga M; Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms. Metab Brain Dis. 2012 Jun;27(2):121-9. doi: 10.1007/s11011-012-9302-1. Epub 2012 Apr 14.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Colin Tidy
Current Version:
Peer Reviewer:
Dr Adrian Bonsall
Document ID:
2279 (v22)
Last Checked:
11/12/2014
Next Review:
10/12/2019

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

 
 
Patient Access app - find out more Patient facebook page - Like our page